Search - tctmd.com

Displaying 461 - 480 of 556

Sort: Relevancy | Date

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Presenter: Prakash Krishnan, Mahmood K. Razavi, Christopher D. Owens

October 11, 2015

Presentation TCT 2015

Update on Bioresorbable Scaffolds for PAD

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Presenter: Gary M. Ansel, Michael R. Jaff, John R. Laird Jr

October 11, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Presentation TCT 2015

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Presenter: Gary M. Ansel, Michael R. Jaff, William A. Gray

October 11, 2015

Presentation TCT 2015

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

Presenter: Gary M. Ansel, Michael R. Jaff, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Below-the-Knee Disease: Salvaging the Limb

Presenter: Julie Logan, Craig M. Walker

October 11, 2015

Presentation TCT 2015

Role of Atherectomy in Lower-Extremity Disease

Presenter: Julie Logan, Roger Gammon

October 11, 2015

Presentation TCT 2015

Do We Need to Reevaluate Our PTA Technique? Lessons Learned From Drug-Eluting Balloons

Presenter: Julie Logan, Krishna J. Rocha-Singh

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Presenter: Julie Logan, George L Adams

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Presenter: Julie Logan, William A. Gray

October 11, 2015

Presentation TCT 2015

Why Is It So Complex? Simplifying Lower-Extremity Disease

Presenter: Julie Logan, Michael R. Jaff

October 11, 2015

News Conference News TCT 2015

Asian TAVR Registry Shows Good Procedural and Clinical Results

October 11, 2015

Presentation TCT 2014

Transradial Peripheral Intervention: What is Feasible? What Equipment Do We Need?

Presenter: Philippe Généreux, Yves R. Louvard, Christopher J J. White

September 16, 2014

Presentation TCT 2014

Cases #9 and #10: Radial Access for Peripheral Intervention

Presenter: Mauricio G. Cohen, Samir B. Pancholy, Tejas Patel, Rajiv Gulati

September 16, 2014

Presentation TCT 2014

Long-term Costs of Directional Atherectomy vs_ Other Treatment Choices for Diabetes Patients with Peripheral Artery Disease: a 24-Month Analysis of Administrative Claims Data

Presenter: Khusrow Niazi

September 16, 2014

Advertisement

Biomimetic Stents: Rationale and Current Clinical Results

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Update on Bioresorbable Scaffolds for PAD

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Below-the-Knee Disease: Salvaging the Limb

Role of Atherectomy in Lower-Extremity Disease

Do We Need to Reevaluate Our PTA Technique? Lessons Learned From Drug-Eluting Balloons

Debate: For SFA Disease I Prefer a Drug-Coated Balloon With Provisional Bare-Metal Stenting

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Why Is It So Complex? Simplifying Lower-Extremity Disease

Asian TAVR Registry Shows Good Procedural and Clinical Results

Transradial Peripheral Intervention: What is Feasible? What Equipment Do We Need?

Cases #9 and #10: Radial Access for Peripheral Intervention

Long-term Costs of Directional Atherectomy vs_ Other Treatment Choices for Diabetes Patients with Peripheral Artery Disease: a 24-Month Analysis of Administrative Claims Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content